http://orcid.org/0000-0003-3606-7672
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Li-Jen Cheng, Grace Wong, Wen-Yee Chay, Joanne Ngeow, Yongqiang Tan, Swee Sung Soon, Mohamed Ismail Abdul Aziz, Fiona Pearce & Kwong Ng. (2021) Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 441-448.
Read now
Read now
Li-Jen Cheng, Lydia Loke, Elaine Hsuen Lim, Fiona Pearce, Mohamed Ismail Abdul Aziz & Kwong Ng. (2021) Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 449-456.
Read now
Read now
Aaron C. Tan, Johan Chan & Mustafa Khasraw. (2021) The role of immunotherapy in fusion-driven lung cancer. Expert Review of Anticancer Therapy 21:5, pages 461-464.
Read now
Read now
Amanda M. Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan, Elizabeth H. Marchlewicz, Christina Chebili-Larson, Stella Min & Deepa S. Subramaniam. (2021) Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US . Journal of Medical Economics 24:1, pages 328-338.
Read now
Read now
Articles from other publishers (6)
Changjin Wu, Wentan Li, Hongyu Tao, Xiyan Zhang, Yu Xin, Ruomeng Song, Kaige Wang, Ling Zuo, Yuanyi Cai, Huazhang Wu & Wen Hui. (2024) Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview. Critical Reviews in Oncology/Hematology 193, pages 104195.
Crossref
Crossref
Hongbin Dai, Wenyue Wang, Xin Fan & Yongfa Chen. (2023) Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China. Frontiers in Medicine 10.
Crossref
Crossref
Chuan Zhang, Jiaxu Zhang, Jing Tan, Panwen Tian & Weimin Li. (2022) Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review. Frontiers in Oncology 12.
Crossref
Crossref
Ting Chen, Ruixiang Xie, Qiuling Zhao, Hongfu Cai & Lin Yang. (2022) Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China. Frontiers in Oncology 12.
Crossref
Crossref
Meng‐Meng Teng, Si‐Ying Chen, Bo Yang, Yan Wang, Rui‐Ying Han, Meng‐Na An, Ya‐lin Dong & Hai‐Sheng You. (2021) Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China. Cancer Medicine 10:18, pages 6344-6353.
Crossref
Crossref
Lydia Loke, Soo‐Chin Lee, Fiona Pearce, Kwong Ng & Mohamed Ismail Abdul Aziz. (2020) Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer Reports 4:1.
Crossref
Crossref